WallStreetZenWallStreetZen

NASDAQ: RGLS
Regulus Therapeutics Inc Stock Ownership - Who owns Regulus Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Regulus Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Preston KlassenPresident Head of R D2025-06-0312,000$7.99
$95.86kBuy
David BaltimoreDirector2025-01-3019,610$1.06
$20.79kBuy
Joseph P. HaganChief Executive Officer2025-01-3050,000$1.09
$54.25kBuy
Christopher Ray AkerSr. VP General Counsel2025-01-145,088$1.26
$6.43kSell
Crispina CalsadaChief Financial Officer2025-01-145,088$1.26
$6.43kSell
Joseph P. HaganChief Executive Officer2025-01-1411,764$1.26
$14.86kSell
Joseph P. HaganChief Executive Officer2025-01-13115,290$1.26
$145.61kSell
Crispina CalsadaChief Financial Officer2025-01-1338,716$1.26
$48.90kSell
Christopher Ray AkerSr. VP General Counsel2025-01-1338,547$1.26
$48.68kSell
Preston KlassenPresident Head of R D2025-01-1331,445$1.26
$39.72kSell

1 of 2

RGLS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when RGLS insiders and whales buy or sell their stock.

RGLS Shareholders

What type of owners hold Regulus Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Federated Hermes Inc22.85%15,819,863$128.30MInstitution
Jon Sakoda15.87%10,989,010$89.12MInsider
Ravi Viswanathan15.87%10,989,010$89.12MInsider
Chetan Puttagunta15.87%10,989,010$89.12MInsider
Ali Behbahani12.28%8,503,510$68.96MInsider
Forest Baskett12.28%8,503,510$68.96MInsider
Mohamad Makhzoumi12.28%8,503,510$68.96MInsider
Carmen Chang12.28%8,503,510$68.96MInsider
Paul Edward Walker12.28%8,503,510$68.96MInsider
Joshua Makower12.28%8,503,510$68.96MInsider

1 of 3

RGLS vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
RGLS23.34%76.66%Net BuyingNet Buying
ALT37.63%62.37%Net SellingNet Buying
AUTL63.13%0.00%
KURA90.71%9.29%Net SellingNet Selling
URGN80.59%19.41%Net SellingNet Selling
View Top Biotech Stocks

Regulus Therapeutics Stock Ownership FAQ

Who owns Regulus Therapeutics?

Regulus Therapeutics (NASDAQ: RGLS) is owned by 78.80% institutional shareholders, 258.87% Regulus Therapeutics insiders, and 0.00% retail investors. Jon Sakoda is the largest individual Regulus Therapeutics shareholder, owning 10.99M shares representing 15.87% of the company. Jon Sakoda's Regulus Therapeutics shares are currently valued at $89.12M.

If you're new to stock investing, here's how to buy Regulus Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.